This panel is a set of blood tests that evaluates levels of prostate-specific antigen (PSA)—a protein made primarily by cells in the prostate gland. The test includes:
PSA is a serine protease enzyme secreted by prostate cells to liquefy semen, which helps sperm motility. Normally, only small amounts of PSA enter the bloodstream. However, when the prostate is enlarged, inflamed, or cancerous, PSA levels can rise. This makes PSA a valuable—but not perfect—biomarker for prostate health.
Benign conditions, such as benign prostatic hyperplasia (BPH) or prostatitis (inflammation of the prostate), can also increase PSA.
Prostate cancer typically causes higher total PSA levels and a lower percentage of free PSA compared to benign conditions.
This is where the PSA Ratio becomes especially helpful. A low PSA Ratio (e.g., <10–15%) may suggest a higher risk of prostate cancer, while a higher ratio is more consistent with benign conditions. However, interpretation must always consider age, prostate size, recent physical activity, infections, and even ejaculation—each of which can influence PSA levels.
Combining total, free, and ratio values improves the accuracy of PSA testing, offering a more nuanced picture than total PSA alone.